Regeneron Pharmaceuticals Inc (REGN)
970.26
+11.62
(+1.21%)
USD |
NASDAQ |
May 07, 16:00
970.26
0.00 (0.00%)
After-Hours: 20:00
Regeneron Pharmaceuticals Accounts Receivable (Quarterly): 5.222B for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 5.222B |
December 31, 2023 | 5.667B |
September 30, 2023 | 5.584B |
June 30, 2023 | 5.121B |
March 31, 2023 | 5.119B |
December 31, 2022 | 5.329B |
September 30, 2022 | 5.548B |
June 30, 2022 | 5.161B |
March 31, 2022 | 4.839B |
December 31, 2021 | 6.036B |
September 30, 2021 | 5.452B |
June 30, 2021 | 6.999B |
March 31, 2021 | 4.173B |
December 31, 2020 | 4.115B |
September 30, 2020 | 3.553B |
June 30, 2020 | 2.380B |
March 31, 2020 | 2.531B |
December 31, 2019 | 2.361B |
September 30, 2019 | 2.66B |
June 30, 2019 | 2.456B |
March 31, 2019 | 2.305B |
December 31, 2018 | 2.243B |
September 30, 2018 | 2.203B |
June 30, 2018 | 2.039B |
March 31, 2018 | 1.944B |
Date | Value |
---|---|
December 31, 2017 | 1.974B |
September 30, 2017 | 1.971B |
June 30, 2017 | 1.845B |
March 31, 2017 | 1.750B |
December 31, 2016 | 1.612B |
September 30, 2016 | 1.644B |
June 30, 2016 | 1.752B |
March 31, 2016 | 1.865B |
December 31, 2015 | 1.468B |
September 30, 2015 | 1.439B |
June 30, 2015 | 1.395B |
March 31, 2015 | 1.338B |
December 31, 2014 | 976.37M |
September 30, 2014 | 927.25M |
June 30, 2014 | 893.92M |
March 31, 2014 | 1.047B |
December 31, 2013 | 954.97M |
September 30, 2013 | 992.82M |
June 30, 2013 | 876.02M |
March 31, 2013 | 802.64M |
December 31, 2012 | 693.12M |
September 30, 2012 | 506.68M |
June 30, 2012 | 349.64M |
March 31, 2012 | 159.46M |
December 31, 2011 | 103.04M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
2.361B
Minimum
Dec 2019
6.999B
Maximum
Jun 2021
4.515B
Average
5.120B
Median
Accounts Receivable (Quarterly) Benchmarks
Vertex Pharmaceuticals Inc | 1.563B |
Amgen Inc | 6.776B |
Eli Lilly and Co | 7.886B |
Moderna Inc | 137.00M |
Gilead Sciences Inc | 4.669B |